Pfizer Caduet Launch Set For May; Inspra Starts Slow
Executive Summary
Pfizer will position the Lipitor/Norvasc combination product Caduet as an "upgrade" for the vast majority of hypertension patients, rather than focus on cannibalizing Norvasc, the company told analysts during an April 20 earnings conference call
You may also be interested in...
Pfizer Lyrica Launch Awaits Controlled Substance Scheduling
Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration
Pfizer Lyrica Launch Awaits Controlled Substance Scheduling
Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration
Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable
The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn